WuXi Advanced Therapies

WuXi Advanced Therapies' Services

WuXi Advanced Therapies offers a comprehensive suite of services tailored to support the development, production, and testing of cell and gene therapies, vaccines, and biologics. Their services include GMP production and testing of cell banks, bioanalytical testing, and the design and manufacture of GMP and GMP-like plasmids. They also specialize in developing, qualifying, and validating testing methods, scaling and optimizing processes for GMP production, and securing data and documentation for IND submissions. This extensive range of services ensures that clients receive end-to-end support from early-stage research to commercial manufacturing.

WuXi Advanced Therapies' Facilities

WuXi Advanced Therapies operates state-of-the-art facilities globally, including locations in Philadelphia, PA; Oxford, UK; Biopolis, Singapore; Tuas, Singapore; Wuxi City, Jiangsu, China; LinGang, Shanghai, China; and WGQ, Shanghai, China. Their Philadelphia campus alone boasts over 400,000 square feet of modern infrastructure, including a purpose-built testing facility with 140,000 square feet of GMP-compliant, flexible laboratory space. These facilities are equipped to handle large-scale manufacturing and clinical trials, supporting the company's ability to meet commercial demand and provide high-quality, high-volume capacity for their clients.

WuXi Advanced Therapies' Technologies

WuXi Advanced Therapies utilizes cutting-edge technologies to enhance their production and testing capabilities. Notable among these are the TESSA® Scalable AAV Production technology and XOFLX™ Packaging and Producer Cell Lines technology. TESSA® technology allows for scalable AAV production with high titer and high-quality outputs, while XOFLX™ provides a streamlined and cost-effective LVV production system. These proprietary technologies enable WuXi Advanced Therapies to deliver efficient and reliable solutions for their clients' advanced therapy needs.

WuXi Advanced Therapies' Achievements

WuXi Advanced Therapies has made significant strides in the cell and gene therapy industry, reflected in their numerous achievements. They have supported over 40 INDs/BLAs and produced over 3,000 GMP lots, cementing their reputation as one of the top 3 cell and gene therapy CDMOs globally. Their parent company, WuXi AppTec, has a vast network of over 41,000 employees across 32 R&D and manufacturing sites worldwide. In recognition of their excellence, WuXi Advanced Therapies received the Frost & Sullivan 2023 Global CDRMO Company of the Year award and the EcoVadis Silver Medal for Sustainability Achievement in 2023.

WuXi Advanced Therapies' Global Team

With a team of more than 1,200 dedicated professionals, WuXi Advanced Therapies leverages a diverse range of expertise to drive innovation and excellence in their services. This global team operates across multiple locations, ensuring seamless collaboration and integration of knowledge and skills. Their commitment to supporting advanced therapies such as CAR-T, T-Cell, TIL, MSC, AAV, Lenti, mAbs, and vaccines underscores their position as a leader in the industry. The company's robust infrastructure and logistics systems, which have passed rigorous inspections, further enhance their ability to deliver high-quality solutions to clients worldwide.